ATLANTA—When it comes to treating rheumatoid arthritis (RA) patients, most clinicians agree: One size does not fit all. Many treatment options exist, and seldom is there 100% consensus on what the first course of action or general approach should be. In the face of such variability, four clinicians took the stage at the 2019 ACR/ARP…
ATLANTA—Osteoporosis in premenopausal women is uncommon compared with its frequency in post-menopausal women, but when it is suspected, it poses some difficult questions for clinicians: How should it be diagnosed in this understudied population? If found, should it be treated—and how? Elizabeth Shane, MD, professor of medicine at Columbia University and attending physician at New…
ATLANTA—Rheumatic diseases have been the subject of a range of public health campaigns and reports over the past decade, but improving their visibility remains a work in progress, a Centers for Disease Control and Prevention (CDC) expert said at the 2019 ACR/ARP Annual Meeting. A growing attention to pain and the opioid crisis may help…
ATLANTA—New drug approvals, new and expanded drug indications, and important safety and other updates relevant for rheumatologists were presented by three physicians from the U.S. Food & Drug Administration (FDA) on Nov. 11 at the 2019 ACR/ARP Annual Meeting. New JAK Inhibitor Approved for RA On Aug. 16, 2019, the FDA approved upadacitinib (Rinvoq), an…
Reproductive health can be a concern for patients with rheumatic diseases, and practitioners in both rheumatology and obstetrics/gynecology often work closely together. The 2020 ACR Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases, new clinical recommendations developed by an ACR-convened group for pregnant women, post-menopausal women, lactating women, and women and…
The evidence-based guideline includes contraceptive recommendations and suggestions for rheumatologists co-managing patients with obstetrician-gynecologists and other specialists.
GCA, GPA, myositis, new research—rheumatology care keeps clinicians on their toes & requires them to stay up to date…
NEW YORK (Reuters Health)—Low-dose methotrexate can be associated with gastrointestinal, pulmonary, infectious, hematologic and other adverse effects, according to an analysis of the Cardiovascular Inflammation Reduction Trial (CIRT). “Methotrexate is not a benign drug, even at dosages used for rheumatic diseases,” Daniel H. Solomon, MD, MPH of Brigham and Women’s Hospital, Boston, tells Reuters Health…
ATLANTA—The potential of cannabis‐based medicines is a hot topic, particularly as pain management therapy for arthritis and other conditions. However, confusion abounds regarding its therapeutic potential, how it can be administered and even the correct terminology to use. David P. Finn, PhD, professor of pharmacology and therapeutics, and founding co-director of the Centre for Pain…
Public health agencies have been raising the profile of arthritis…